about
Riluzole elevates GLT-1 activity and levels in striatal astrocytesLocomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathwayThe group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated ratThe 5HT(1B) receptor agonist, CP-93129, inhibits [(3)H]-GABA release from rat globus pallidus slices and reverses akinesia following intrapallidal injection in the reserpine-treated ratBrain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulationGroup III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo.The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Changes in GABA(B) receptor mRNA expression in the rodent basal ganglia and thalamus following lesion of the nigrostriatal pathway.Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's diseaseGABA(B) receptor agonists reverse akinesia following intranigral or intracerebroventricular injection in the reserpine-treated rat.Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat.Chronic pre-treatment with nicotine enhances nicotine-evoked striatal dopamine release and alpha6 and beta3 nicotinic acetylcholine receptor subunit mRNA in the substantia nigra pars compacta of the rat.Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in ratsEffect of unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway on GABA(A) receptor subunit gene expression in the rodent basal ganglia and thalamusChanges in [3H]zolpidem and [3H]Ro 15-1788 binding in rat globus pallidus and substantia nigra pars reticulata following a nigrostriatal tract lesionPain in Parkinson's disease: new concepts in pathogenesis and treatmentChondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's diseasePotential of animal models for advancing the understanding and treatment of pain in Parkinson's disease
P50
Q24610013-E7684C01-ED5D-409B-A442-248132F52746Q24671046-8ACA0143-8937-4089-BFB5-2AD94C6B9533Q24675262-0F6F96C9-4A57-4A1A-985D-ECD35723470EQ28344635-FB13C73D-6737-4B3A-A046-D5364BA3F4F6Q30833645-024731E5-FE94-40D2-A890-CABBE57E731CQ34223052-00AAF492-5E00-4290-8EB3-53FED8AC9547Q34717897-71070375-E43C-4459-82AA-F37959C2343FQ35137388-87EDB64F-4942-4B30-916F-0AD858C13248Q35589979-87C6452F-6B15-48D6-8757-2C9338EDE31AQ37782115-1720A69B-EF95-442D-A6EA-0B3263D124D7Q38190016-ECC61435-BBA4-4DA1-92B5-9E71521BD2B4Q38351332-8A33D787-CBB2-4B8B-8486-C981A80D1EEFQ39282544-9A0AE69C-D0D6-4A0D-8557-32A3983E6B88Q41874777-854D83CC-984C-44A2-98CE-8E36A6015E6DQ43263145-1CEA958C-947F-4ED9-864C-5BAD06EC66FAQ46695376-BF53E2D8-D709-487A-AFBE-09E2B323E70FQ48380016-641FCA3A-B661-4FB7-BF95-564B14FFBD1DQ53401190-F4C929A8-3F2C-4B13-83A1-3B00617DD9BFQ64764542-9678A2C7-B6AE-41D6-AA5F-3180E48AFCEDQ73320614-B9FFE78B-C3E6-4DFF-B03E-5958C38DA0FBQ73755368-69D4C663-BEC5-40D9-B239-A07E56FE46DDQ91508769-6C02E1AC-FC32-4106-A9B8-B3D6028FE53BQ92157515-7D4D672D-0FF1-44EF-ADF3-BEA4C9D55F57Q92622174-8402D14E-7170-4713-B2C9-B3A3BEDECF53
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-3408-5973
@en
name
Susan Duty
@ast
Susan Duty
@en
Susan Duty
@es
Susan Duty
@nl
type
label
Susan Duty
@ast
Susan Duty
@en
Susan Duty
@es
Susan Duty
@nl
prefLabel
Susan Duty
@ast
Susan Duty
@en
Susan Duty
@es
Susan Duty
@nl
P106
P1153
56008678200
P21
P31
P496
0000-0003-3408-5973